High-flow nasal cannula for acute respiratory failure in patients with coronavirus disease 2019 in a Japanese single-center, retrospective, observational study: 1 year of clinical experience
Description
Data set associated with the publication "High-flow nasal cannula for acute respiratory failure in patients with coronavirus disease 2019 in a Japanese single-center, retrospective, observational study: 1 year of clinical experience "
Files
Steps to reproduce
From January 2020 to January 2021, we retrospectively analyzed 513 consecutive patients with COVID-19 who were admitted to our hospital. We included patients with moderate COVID-19 who received HFNC treatment owing to their worsening respiratory status. There was no protocol in place regarding HFNC, and its use was at the discretion of individual clinicians in cases where oxygen saturation could not be maintained with conventional oxygen therapy. The F&P 850 system (Fisher & Paykel Healthcare, Auckland, New Zealand) was used to provide HFNC therapy. The HFNC gas temperature was set at 31°C (humidity: 32 mg/L) or 37°C (humidity: 44 mg/L), depending on the patient’s preference. HFNC success was defined as an improvement in respiratory status after HFNC and transfer to conventional oxygen therapy, and HFNC failure was defined as transfer to non‐invasive positive pressure ventilation (NPPV) or ventilator, or death after HFNC.